Reason for request
New indication
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of ENHERTU (trastuzumab deruxtecan) is substantial “as monotherapy in adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received at least two prior trastuzumab-based treatment lines”.
|
| Insufficient |
Considering all these elements, the Committee deems that the clinical benefit of ENHERTU (trastuzumab deruxtecan) is insufficient in the other situations of the MA indication extension - i.e. as second-line therapy - to justify public funding cover.
|
Clinical Added Value
| minor |
Considering:
- demonstration of a superiority in the phase 2 DESTINY-Gastric01 study of T-DXd treatment compared to treatment of the physician’s choice (TPC) in terms of:
- ORR (primary endpoint) with a differential of + 37.0% (CI95% = [41.9; 60.5] in the T-DXd group and CI95% = [6.4; 26.2] in the TPC group; p < 0.0001) in favour of T-DXd,
- OS (ranked secondary endpoint) with a differential of + 4.1 months (HR = 0.59, CI95%: [0.39; 0.88]; p=0.0097) in favour of T-DXd,
- the inadequately met medical need insofar as the efficacy of LONSURF (trifluridine / tipiracil) is limited with short median PFS and OS durations;
and despite:
- the lack of demonstration of any superiority of T-DXd treatment compared to the LONSURF comparator (trifluridine / tipiracil);
- questions concerning the transposability of the results of the DESTINY-Gastric01 study, conducted in Asia only;
- an excess haematotoxicity (neutropenia, anaemia, leukopenia, lymphopenia and thrombocytopenia);
- the risk of diffuse interstitial lung disease/pneumonitis, identified as an important risk in the RMP;
- the absence of a demonstrated impact on quality of life (exploratory endpoint).
the Committee deems that ENHERTU (trastuzumab deruxtecan) provides a minor clinical added value (CAV IV) in the current care pathway as third or later-line treatment, which includes LONSURF (trifluridine / tipiracil).
|
| Not applicable |
|
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
fA5e1nuf2nnCVm8w